Susan Molineaux

Insider Reports History

Location
South San Francisco, CA
Signature
Scott A. Samuels, attorney-in-fact for Susan Molineaux
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Susan Molineaux:

Form 4 holding PRESIDENT & CEO, Director

Calithera Biosciences, Inc.

Security class
Common Stock
Shares / value
27,859
Estimated value
$10,748
Report date
23 Jan 2023
Price
$0.3858
Ownership
By Trust
Form 4 holding PRESIDENT & CEO, Director

Calithera Biosciences, Inc.

Security class
Common Stock
Shares / value
5,283
Estimated value
$2,038
Report date
23 Jan 2023
Price
$0.3858
Ownership
By Spouse
Form 4 holding PRESIDENT & CEO, Director

Calithera Biosciences, Inc.

Security class
Common Stock
Shares / value
4,724
Estimated value
$1,823
Report date
23 Jan 2023
Price
$0.3858
Ownership
Direct
Form 4 holding Director

GERON CORP

Security class
Stock Option (right to buy)
Shares / value
180,000
Estimated value
Report date
21 May 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Repare Therapeutics Inc.

Security class
Stock Option (right to buy)
Shares / value
27,200
Estimated value
Report date
17 Jun 2024
Price
Ownership
Direct
Underlying class
Common Shares
Underlying amount
Form 4 holding Director

Cyteir Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
14,150
Estimated value
Report date
03 Feb 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Susan Molineaux

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .